The expression and clinical signification of EGFR and HER2 in the serum and tumor tissue of colorectal cancer

SONG Jun-fei; LIU Yi

doi:10.16462/j.cnki.zhjbkz.2016.04.020

Volume 20 Issue 4

Apr. 2016

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2016 > 20(4): 403-407

SONG Jun-fei, LIU Yi. The expression and clinical signification of EGFR and HER2 in the serum and tumor tissue of colorectal cancer[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(4): 403-407. doi: 10.16462/j.cnki.zhjbkz.2016.04.020

Citation:

SONG Jun-fei, LIU Yi. The expression and clinical signification of EGFR and HER2 in the serum and tumor tissue of colorectal cancer[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(4): 403-407. doi: 10.16462/j.cnki.zhjbkz.2016.04.020

Citation:

PDF( 1094 KB)

The expression and clinical signification of EGFR and HER2 in the serum and tumor tissue of colorectal cancer

doi: 10.16462/j.cnki.zhjbkz.2016.04.020

SONG Jun-fei,
LIU Yi^,

Department of General Surgery Ward Two, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Received Date: 2015-11-08
Rev Recd Date: 2016-02-25

Abstract

Abstract

Objective To observe the expression level of epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor-2 (HER2) in colorectal cancer (CRC) and discuss the role of EGFR and HER2 in CRC occurrence and development, so as to offer a possible new biomarker for diagnosis and prognosis of CRC. Methods Immunohistochemical (IHC) was used to detect the expression of tissue EGFR and HER2 in 76 cases of CRC primary lesion and normal tissue adjacent to carcinoma, 40 cases of colorectal adenomas. Preoperative serum samples were extracted from 76 cases of CRC and 40 healthy volunteers. Serum levels of EGFR and HER2 were determined by the enzyme-linked immunosorbent assays (ELISA). Results There was significant difference between the overexpression of EGFR and HER2 in CRC and the low expression in normal mucosa and adenoma(all P<0.05). Serum EGFR(t=14.845, P<0.001) and HER2 (t=15.410, P<0.001) were significantly higher in patients with CRC than those in normal control group. The level of EGFR and HER2 expression in tissue was correlated with lymph node metastasis and Dukes stage(all P<0.05), while without relation with sex, age,etc(all P>0.05). Conclusions The overexpression of EGFR and HER2 in CRC tissue and serum suggests that the expression of EGFR and HER2, and with the development of transfer the degree of tumor infiltration increased, which may play an important role in the occurrence and progress of CRC. Serum EGFR and HER2 can be used as new tumor markers.
- Colorectal neoplasms,
- Receptor, epidermal growth factor,
- Epidemiologic methods

FullText(HTML)

References(22)

References

Tsigris C, Karayiannakis AJ, Zbar A, et al. Clinical significance of serum and urinary c-HER2 levels in colorectal cancer [J]. Cancer Lett, 2002,184(2):215-222.

吴凡,叶韵斌,陆俐丽,等. 乳腺癌患者血清HER2的检测及其临床意义 [J]. 中国肿瘤生物治疗杂志, 2009,16(4):405-409.

Streckfus C, Bigler L, Dellinger T, et al. The presence of soluble c-HER2 in saliva and serum among women with breast carcinoma: a preliminary study [J]. Clin Cancer Res, 2000,6(6):2363-2370.

Kang SH, Cho J, Ha JS, et al. Evaluation of serum HER-2/neu extracelluar domain in breast cancer patients:correlation with tissue HER-2/neu status and clinicopathological factors [J]. J Korean Surg Soc, 2010,78(5):271-276.

Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments [J]. Pathology, 2012,44(7):587-595.

Abdel-Aziz MM, Lotfy M, El-Kady IM, et al. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor [J]. Cancer Detect Prev, 2009,32(4):329-335.

焦裕荣,邵正萍,丁克峰. 结直肠癌转移的防治进展 [J]. 实用肿瘤杂志, 2014,29(6): 510-516.

王宁,孙婷婷,郑荣寿,等. 中国2009年结直肠癌发病和死亡资料分析 [J]. 中国肿瘤, 2013,22(7):515-520.

杨辉,朱瑞凯,冯向先,等. 1381例结直肠癌患者住院费用分析 [J]. 中华疾病控制杂志, 2014,18(7):679-682.

刘茉,王亚东,王贵齐,等. 基于慢病管理的结直肠癌筛查模式初探 [J]. 中华疾病控制杂志, 2015,19(5):525-527.

Leporrier J, Maurel J, Chiche L, et al. A population‐based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer [J]. Br J Surg, 2006,93(4):465-474.

Xue Y, Yu F, Yan D, et al. Zinc-α-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population [J]. Int J Mol Sci, 2014,16(1):691-703.

曾瑄,王鹏,武莎斐,等. 结直肠癌EGFR和HER2蛋白表达及其基因拷贝数分析 [J]. 中华病理学杂志, 2007,36(7):447-452.

Lu Y, Jingyan G, Baorong S, et al. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer [J]. Cancer Biomark, 2012,11(5):219-226.

Sasaki H, Yukiue H, Mizuno K, et al. Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer [J]. Int J Clin Oncol, 2003,8(2):79-82.

Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer [J]. Ann Surg Onco, 2003,10(3):234-241.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J]. Lancet, 2010,376(9742):687-697.

Mukai H. Targeted therapy in breast cancer: current status and future directions [J]. Jpn J Clin Oncol, 2010,40(8):711-716.

Half E, Broaddus R, Danenberg KD, et al. HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors [J]. Int J Cancer, 2004,108(4):540-548.

Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer [J]. Oncology, 2010,78(1):26-33.

Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery [J]. Ann Surg Oncol, 2006,13(6):823-835.

Oyama K, Fushida S, Tsukada T, et al. Evaluation of serum HER2-ECD levels in patients with gastric cancer [J]. J Gastroenterol, 2015,50(1):41-45.

Relative Articles

Supplements(0)

Cited By

Proportional views